

APPEND

TRANSLATION FROM PORTUGUESE TO  
ENGLISH OF THE BRAZILIAN PRIORITY  
DOCUMENT PI 0305339-3

"PROCESS OF OBTAINING 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one CRYSTALS FOR USE IN GLUCOSED SERUM; SOLUTION BASED ON SAID CRYSTALS FREE FROM ALKALINE RESIDUES; PROCESS AND USE OF CLOSED SYSTEM IN THE PACKAGING OF THE SOLUTION; 5 AND USE OF THE SOLUTION AND OF THE SYSTEM IN THE TREATMENT OF DESEASES."

**FIELD OF THE INVENTION**

The present invention describes a process to obtain 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one crystals free from alkaline residues. The pre-diluted solution comes ready for administration to the patient, being stored in closed system, being avoided the risks of contamination. It also refers to an injectable solution of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one pre-diluted in glucose, to the process of 15 packaging of the injectable solution obtained in closed system, and to the use of the said crystals in glucosed serum.

**BACKGROUND OF THE INVENTION**


Gancyclovir (9-((1,3-Dihydroxy-2-propoxy)methyl)guanine or DHPG, or 2-Amine-1,9-((2-hydroxy-1-(hydroxymethyl) ethoxy)methyl)-20 6-H-purin-6-one, or 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1H-purin-6(9H)- one) is a synthetic drug derived from acyclovir, as described in patent US 4,355,032, showing to be active against most of herpes virus, with an activity of 100 times greater against cytomegalovirus. It was approved as a 25 pharmaceutical drug in 1989, as an intravenous solution for treating retinitis in immunodepressed patients. Because its toxicity, it is only used for treating seriously immunodepressed patients, like AIDS infected and immunotransplanted individuals presenting serious disease related to cytomegalovirus infection.

30 In herpes simplex virus infected cells the mechanism of action is the same of Acyclovir. Cytomegalovirus does not have viral specific thymidine kinase, but the initial Ganciclovir


phosphorylation is done by a phosphotransferase encoded by the virus gene.

Pretty much similar to Acyclovir - which is the nucleoside with the best therapeutic index among antiviral agents used for  
5 treating herpes simplex virus (HSV) infections type 1, type 2 and varicella zoster - in relation to the mechanism of action, initially it was used for treating immunodepressed patients infected by cytomegalovirus. It acts in two ways: by competitive inhibiting viral DNA-polymerase and by direct incorporation into  
10 viral DNA. It possess a broad spectrum activity including Epstein-Barr virus, cytomegalovirus, adenovirus, herpes zoster virus, and herpes virus types 1 and 2. Its efficacy, tolerance, and intraocular penetration was demonstrated by experimental studies of herpes keratitis in rabbits.

Acyclovir.



Gancyclovir.



15 The 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, as its sodium salt, is commercialized as a lyophilized powder. The lyophilized product is prepared by dissolving the active pharmaceutical ingredient (free acid form) in sodium hydroxide and it is submitted to sterile filtration, filling and subsequent lyophilization, so obtaining the lyophilized within the accepted technical specifications.

The manufacturer of the lyophilized powder recommends that preparations of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one sodium salt in compatible infusion solutions, must

be stored under refrigerating, but not under freezing. The 9-((1,3-dihydroxypropan-2-iloxy) methyl)-2-amino-1H-purin-6(9H)-one once reconstituted by using sterile water for injection and diluting with sodium chloride 0.9% solution in PVC bags, it is physically  
5 and chemically stable for 14 days when stored under refrigeration at 5°C. However, because the absence of preservative antimicrobial agents, it is recommended to be used within 24 hours (Reference: Lawrence A. Trissel - Handbook on Injectable Drugs 11th edition, pages 613 to 616).

10 In counterpart, the new formulation in a closed system disclosed in this application is sterile and stable for at least 24 months when stored at room temperature (20 to 30°C).

According to Brazilian application PI9803096 from LABOGEN S/A QUIMICA FINA E BIOTECNOLOGIA, the current marketed presentation of  
15 lyophilized 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one sodium salt can be improved in matter of process as well as the product itself, and this application, mentioned just as a reference from the state of the art, discloses the pharmaceutical active ingredient as alkaline salts of sodium and potassium, in an  
20 aqueous solution enclosed in ampoules with a concentration suitable for direct administration, and sterilized for assuring its chemical and microbiological properties. The resulting product is transferred into glass ampoules, sterilized by autoclaving and preserved within the useful definite conditions for the final  
25 client.

#### **THE CLOSED SYSTEM**

The concept of closed system for parenteral solutions is based in the fact that there is no contact between the environment and  
30 the solution to be administered, by this way avoiding the microbiological contamination by air or by contact during the connection of the administration equipment.

Parenteral solutions may be packed in plastic flasks being designated as open systems, where there is no total protection against contamination. In this case, during the administration of the product to a patient vacuum develops, slowing the rate of the 5 dropping solution. Besides, other drugs are added by withdrawing the device connected to the flask incurring in higher risks of contamination.

Packing 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one in closed systems with glucose or sodium chloride 10 solution where not feasible until now because the instability of Ganciclovir sodium salt diluted in sodium chloride 0.9% and glucose 5% solutions, because an alkaline pH (about 11) is not compatible with the pH of those solutions (sodium chloride, Ringer lactate and glucose tolerate a maximum pH of 6).

Starting from this principle, the present invention proposes 15 packing the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one as its free acid form with glucose or sodium chloride solution in a closed system, thus avoiding the existing inconveniences found in the state of art, including those observed 20 in packed ampoules.

#### **THE INVENTION**

In the production of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one in glucose solution it was possible to notice the development of yellow coloration during the 25 sterilization process and during accelerated stability studies, where the product was submitted to high temperatures, which indicated degradation. It was possible to reach a stabilized product by the technology of the present invention, by altering the kind of crystal from 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-30 amino-1H-purin-6(9H)-one molecule (Ganciclovir).

By this observation, the present invention concludes that the use of pre-diluted preparations in a closed system reduces

medicines administration errors, reducing manipulation steps performed by nursing personnel, as well reducing contamination risks.

The product resulting from the present invention presents 5 itself as a glucose or sodium chloride 0.9% solution with 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, which can be packed in a flexible plastic bag (closed system).

The flexible bag used in the closed system with the new 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one 10 formulation is made by a film composed by three distinct layers, each one of them with a singular protection function. The process for producing the film is called co-extrusion, where the layers are grouped together forming a single sheet. The outer layer is made of polyester, a heat resistant material, with optimum transparency and 15 optimum resistance to abrasion and mechanical stress. The intermediate layer is made of polyethylene giving excellent flexibility and, because its intrinsic properties, works as a barrier against moisture and vapors exchange with the environment. The inner layer is made of propylene copolymer that is impermeable 20 and posses excellent flexibility; its main characteristic is that it is chemically inert and do not interact with the product filled within. All this characteristics make the tri-laminated the excellence packing when compared to PVC, which besides presenting 25 plastifying and additive substances interacts with the product stored for longer periods of time.

As one of its objectives, the present invention describes a process for preparing the pharmaceutical active ingredient, 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, in its elementary form (free acid form or non saline), without free 30 alkaline residues resulting from the manufacturing process by its purification/crystallization.

The product of the present invention presents as its main characteristics the fact of being stable, being adequate to be stored in a closed system by a sterile plastic bag, being sterile, presenting a pH suitable for its storing in a closed system as a glucose or sodium chloride solution, which is the same pH of the solution. The stabilization of the final solution was possible because of the alteration of the kind of crystal from 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, which can be achieved by the process for eliminating alkaline residues that are present in the crystals.

The altering in the active pharmaceutical ingredient crystal state resulting from the process, among them - shape, size, particle size, clearness, etc., characterizes another peculiar aspect of the active agent so prepared that differences itself from the product described in the state of art.

So, the present invention is centered in the process of altering the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one crystals and the final characteristics from this crystals, as well as its function for the obtaining of the pharmaceutical product target of the present invention for the packaging in closed system.

The active pharmaceutical ingredient without free alkaline residues is essential for preparing one of the new pharmaceutical presentations of the product, in glucose solution, once the glucose, a starting material of the glucose solution with 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, reacts with alkalis forming furfural and methyl furfural, and these reacts with 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one present in the glucose solution generating further undesired substances, still under research.

During its purification/crystallization the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one (free

acid form), generates crystals with the inclusion of some parts per billion (PPB) of alkaline residues. These alkaline residues are responsible for glucose degradation and, therefore, provoke the degradation of 9-((1,3-dihydroxypropan-2-iloxy) methyl) -2-amine-1H-purin-6(9H)-one present in the glucose solution.

The process for preparing the active pharmaceutical ingredient crystals free from alkaline residues starts by preparing a suspension of 90 to 110g, preferably 100g of 9-((1,3-dihydroxypropan-2-iloxy) methyl) -2-amine-1H-purin-6(9H)-one (free acid form) in 0.9 to 1.1L, preferably in 1L of demineralized water. Next, it is added 13.5 to 16.5g, preferably 15g, of inorganic bases like potassium hydroxide, lithium hydroxide, sodium hydroxide (caustic soda), preferably sodium hydroxide, until reaching a pH from 10.5 to 12.5, when all solids dissolve forming a solution. When using caustic soda the preferential amount is about 15g and the preferential pH is 11.5. Next, the solution is heated to a temperature ranging from 75° to 90°C, preferably 85°C, and 5.4 to 6.6g, preferably 6g, of acids like fuming hydrochloric acid, hydrofluoric acid, acetic acid, citric acid are added until reaching a pH ranging from 4.5 to 5.5, preferably 4.5. Then the solution is cooled to a temperature ranging from 5° to 7°C, preferably 5°C, crystallizing the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1H-purin-6(9H)-one (free acid form). After 25 to 40 minutes, preferably 30 minutes, under the temperature described above, the solid is filtered and washed with organic solvents like isopropanol, acetone, ethanol, methanol, preferably isopropanol. After the filtration, the resulting solid of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one (free acid form) is suspended in isopropanol and intensely refluxed for 3 to 4 hours, preferably 4 hours. Then the resulting suspension is cooled to room temperature, between 20° to 30°C, preferably 25°C, and it is immediately filtered. The solid of 9-((1,3-

dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one (free acid form) is dried in vacuum oven for 3 to 5 hours, preferably 4 hours at a temperature ranging from 60° to 80°C, preferably 70°C, so obtaining 90.4g to 100.4g, preferably 95.4g of the dried product.

5 More detailed, the process of the present invention starts in a glass reactor coupled with a condenser apparatus wherein the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one is suspended in demineralized water, under strong stirring, under room temperature until complete homogenization.

10 The proportion of demineralized water used in relation to 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one is preferably 10 parts, although it is possible to use from 8 to 20 parts achieving the same effect.

15 Under stirring, sodium hydroxide (caustic soda) is added in an equivalent amount of 1.1 mol of sodium hydroxide in relation to 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, there is the total dissolution of the suspension. It is possible to use 0.9 to 2.0 moles of sodium hydroxide per mole of the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, 20 preferably 1.1 moles.

Other inorganic bases that can be used are: potassium hydroxide and lithium hydroxide. Preferably sodium hydroxide is used. After that, under stirring, the temperature of the solution is raised to 75 to 90°C, preferably 85°C, and fuming hydrochloric acid (or other acid like hydrofluoric, acetic, citric, preferably hydrochloric acid is used) is added until the solution reaches a pH ranging from 4.5 to 5.5, preferably 4.5, by using approximately 5.4g to 6.6g, preferably 6g of hydrochloric acid.

25 After adjusting the solution pH the solution is cooled under stirring to a temperature of 5 to 7°C, preferably to a temperature of 5°C, in order to crystallize the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one. The system is kept under

stirring under this temperature for a period of time of 25 to 40 minutes, preferably for 30 minutes and then the suspension is filtered, washing the solid with water at a temperature of 5 to 7°C, in a ratio of 1/10 of the water volume used in the beginning 5 of the process, and then the solid is washed with isopropanol kept at a temperature from 5 to 7°C in a ratio of 1/10 of the water volume used in the beginning of the process. It is possible to use other organic solvents instead isopropanol, like: acetone, ethanol, methanol. Preferably isopropanol is used. The resulting solid of 9-  
10 ((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one is transferred to a glass lined reactor with a reflux condenser and isopropanol is added in a ratio of 4 to 6 parts in relation to the solid mass of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, preferably using 4 parts, and under stirring this  
15 suspension is heated until refluxing.

Other organic solvents can be used instead isopropanol, like: acetone, ethanol, methanol. Preferably isopropanol is used. The system is kept under reflux for 3 to 4 hours. The suspension is cooled to a temperature from 20 to 30°C and it is filtered. The 20 resulting solid of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one is dried in a vacuum oven during 3 to 4 hours at a temperature from 60 to 80°C. The final yield of the procedure is between 89 to 98%.

The present invention solves this problem from the state of 25 art by a formulation prepared in an acid pH, that can be directly obtained by the process for treating the crystals of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one by the crystallization in an acid pH as described in the process for eliminating the alkaline residuals.

30 The crystal of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one resulting from the process presents ideal

conditions for being added to sodium chloride 0.9 or glucose solution without presenting degradation.

The earlier tests were tried with the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one molecule used for 5 preparing the lyophilized product. As result, there was obtained a yellowish and oxidized solution because of the high pH, that did not stabilize the glucose solution.

By altering the crystallization molecule of sodium Ganciclovir previously achieved by LABOGEN, a clear and non-oxidized solution 10 with pH of about 5.5 was achieved. Stabilizing the molecule in this pH, allowed lowering hazards during manipulation, once the previous solution was too much alkaline (pH=11), and was too much irritating after its reconstitution being not possible to be in contact with the skin, mucous membranes and eyes. Using appropriate glasses and 15 gloves were necessary when manipulating this substance.

In accordance with protocols from the American Society of Hospital Pharmacy - ASHP, Ganciclovir must be manipulated and prepared inside laminar flow chambers, thus preventing the contamination of the product by microorganisms and protecting the 20 person and the environment from potential risks of the medicament. The appropriate equipment carrying this operation is a class II vertical laminar flow chamber BSC (bio-security chamber).

As the solution of the present invention is pre-diluted ready for the administration to a patient, manipulating steps by the 25 nursing personnel from the hospital are minimum, the risks of contamination and the security of the operator are preserved. The product from the present invention in the closed system will eliminate the need of acquiring laminar flow equipments for preparing the medicament.

30 The pH of the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one as a solution in a closed system was significant altered, making its manipulation easier, increasing the security to

the operator, lowering contamination risks and expenses regarding equipments, specific areas and employees for its manipulation. The toxicity risk, like carcinogenicity and mutagenicity for the operator was eliminated, once the product is ready for  
5 administration.

By altering the pH, the solution does not provoke abscess or phlebitis, risks existing in the previous formulation (vial with lyophilized powder - ROCHE).

With the new presentation in a closed system, it is possible  
10 to observe that one step of the process was facilitated. Considering the particle size distribution of the starting material, the grinding step required for the production of the lyophilized powder can be eliminated, as during the process for manipulating 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one in solutions it is used high stirring reactors that  
15 promote an efficient dissolution assured by particle counting tests.

Laboratory tests performed were active pharmaceutical ingredient assay (ganciclovir) by HPLC, diluents analysis (sodium  
20 chloride and glucose) by photometry and polarimetry, pH potentiometric determination, particle counting, accelerated stability tests, search for degradation products by spectrophotometry (hydroxymethyl furfural) and microbiological analysis. *In vivo*, pyrogen testing in rabbits.

25 During the production (purification/crystallization) of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one (free acid form), crystals are generated with the inclusion of some parts per billion of alkaline residues. These alkaline residues are responsible for glucose degradation and therefore provoke the  
30 degradation of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one present in the glucose solution. The answer found was to eliminate the residue, searching for a new

crystallization way, in acidic pH, and so, free from alkaline residues and, consequently, a new crystal form was obtained, which results demonstrate a great improvement in the stability of the product in glucose and sodium chloride solutions with 9-((1,3-  
5 dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one.

According to the process for eliminating alkaline residues described before, the active pharmaceutical ingredient 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one is prepared in its elemental form (free acid form), without free  
10 alkaline residues, a primordial issue for preparing the new product presentation in glucose solution.

Studies demonstrate that free alkaline residues causes glucose degradation, a starting material present in the formulation of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one  
15 product, forming furfural and methylfurfural that react with 9-((1,3-dihydroxypropan-2-iloxy) methyl) -2-amine -1H-purin-6(9H)-one originating further substances still under study.

During the production (purification/crystallization) of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one  
20 (free acid form), crystals are generated with the inclusion of some parts per billion of alkaline residues. These alkaline residues are responsible for glucose degradation and therefore provoke the degradation of 9-((1,3-dihydroxypropan -2-iloxy) methyl)-2- amine-1H-purin-6(9H)-one present in the glucose solution. The answer  
25 found was to eliminate the residue, searching for a new crystallization way, in acidic pH, and so, free from alkaline residues and, consequently, a new crystal form was obtained, which results demonstrate a great improvement in the stability of the product in glucose and sodium chloride solutions with 9-((1,3-  
30 dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one.

During long term stability study, hydroxyethyl furfural, which is a glucose degradation product, was monitored in Ganciclovir in

glucose solution. Tests were performed at the beginning, at 12 months and 24 months. The presence of hydroxyethyl furfural comes from glucose degradation when submitted to outside specified pH limits and sterilization beyond time and temperature specified  
5 limits.

Therefore, the change of the molecule of crystallization of the sodium ganciclovirate checked innovative characteristics to the solution of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one to condition it in aseptic conditions and with  
10 stability in the closed system.

With this new pharmaceutical presentation, other medicine associations can be easily done, which could not be possible with the initial formulation because its strong alkaline pH: Doxorubicin HCl, Etoposide phosphate, Fluconazole, Sodium Methotrexate,  
15 Sargramostim and Thiotepea, in ordinary usual dosages.

Considering that the therapeutic dosage of the lyophilized reconstituted product is 5mg/kg by intravenous infusion every 12 hours during 14 to 21 days, we need the results from the clinical trials in order to delineate necessary adjustments of the  
20 therapeutic method for the inventive product stored in a closed system.

#### **EXAMPLE I:**

PROCESS FOR PREPARING 9-((1,3-DIHYDROXYPROPAN-2-ILOXY) METHYL)-2-AMINE-1H-PURIN-6(9H)-ONE FREE ACID FORM IN ITS ELEMENTAL FORM,  
25 WITHOUT FREE ALKALINE RESIDUES

To a suspension of 100g of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one in 1L of demineralized water add 15g of caustic soda, pH 11.5, total dissolution takes place. After that, raise the temperature of the solution to 85°C  
30 and add about 6g of fuming hydrochloric acid until pH = 4,5. The solution is cooled to 5°C and 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one (free acid form)

crystallizes. After 30 minutes under stirring at 5°C, the solid is filtered and washed with isopropanol. The solid of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one (free acid form) is suspended in isopropanol, under intense reflux, for 4 hours. The suspension is cooled to room temperature (25°C) and is immediately filtered. The resulting solid of 9-((1,3-dihydroxypropan -2-iloxy ) methyl)-2-amine-1H-purin-6(9H)-one (free acid form) is dried in vacuum oven for 4 hours at a temperature of 70°C, yielding 95.4g of the dried compound.

10

## EXAMPLE II

### PROCESS FOR PREPARING 9-((1,3-DIHYDROXYPROPAN-2-ILOXY) METHYL)-2-AMINE-1H-PURIN-6(9H)-ONE FREE ACID FORM IN ITS ELEMENTAL FORM, WITHOUT FREE ALKALINE RESIDUES

In a glass reactor equipped with a reflux condenser suspend the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one in demineralized water, in a ratio of 10 parts of demineralized water in relation to 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, under strong stirring at room temperature until complete homogenization. To the resulting suspension add under stirring sodium hydroxide (caustic soda), in an equivalent amount to 1.1 moles of sodium hydroxide in relation to 9-((1,3-dihydroxypropan -2-iloxy) methyl) -2-amine-1H-purin-6(9H)-one, total dissolution of the suspension takes place. After that, under stirring, raise the temperature of the solution to 85°C and add fuming hydrochloric acid until pH of the solution is 4.5, using about 5.4 to 6.6g of hydrochloric acid. After the solution pH adjustment, start its cooling under stirring until temperature reaches 5°C, in order to crystallize the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one. The resulting suspension is kept under stirring at that temperature for 30 minutes and then it is filtered, the solids being washed with water kept at a temperature of 5 to 7°C in a ratio of 1/10 of the volume of water

used in the beginning of the process and then it is washed with isopropanol kept under a temperature of 5 to 7°C in a ratio of 1/10 of the volume of water used in the beginning of the process. The resulting solid of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-  
5 1H-purin-6(9H)-one is transferred to a glass lined reactor equipped with a reflux condenser, isopropanol is added in a ratio of 4 parts in relation to the solid mass of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one and, under stirring, this suspension is heated to reflux temperature. Reflux is kept for 3 to  
10 4 hours. The suspension is cooled to a temperature between 20 and 30°C and filtered. The resulting solid of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one is dried in vacuum oven for 3 to 4 hours at a temperature ranging from 60° to 80°C. The final yield is between 89 to 98%.

15 **TABLE 1: SATBILITY STUDY**

Product: Ganciclovir in glucose 5% solution (1mg/mL)

Batch Number: Pilot 1 Manufacturing Date: Feb/2000

Batch size: 100 units

Packing: Tri-laminate plastic bag - 250mL

20 Results:

**Long term stability Study - 30°C ± 2°C:**

Tests	Specification	Beginning	6 months	9 months	12 months	24 months
<b>Description/color</b>	Clear colorless liquid	Conforms	Conforms	Conforms	Conforms	Conforms
<b>Assay Ganciclo-vir</b>	90% to 110%	101.2	100.8	99.5	99.7	98.7
<b>Assay Glucose</b>	95% to 105%	99.8	99.2	99.4	98.8	98.0
<b>pH</b>	3.2 to 6.5	5.8	5.4	5.5	5.7	5.5
<b>Sterility</b>	Sterile	Sterile	-	-	-	Sterile
<b>Pyrogen</b>	Non-pyrogenic		-	-	-	Non-pyrogenic

<b>Number of analyzed samples</b>		13 units	3 units	3 units	3 units	13 units
---	--	----------	---------	---------	---------	-------------

Accelerated Stability:

The Injectable solution of Ganciclovir in glucose 5% was submitted in its primary packing to study in ovens at temperatures of 40°C and 50°C for periods of 180 and 90 days respectively. Bags placed at 40°C were analyzed in periods of 30, 60, 90 and 180 days, and bags placed at 50°C were analyzed in periods of 30, 60 and 90 days.

<b>Tests</b>		<b>Aspect: Clear colorless liquid</b>	<b>pH : 3.2 to 6.5</b>	<b>Glucose Assay: 95% to 105%</b>	<b>Ganci- clovir Assay: 90% to 110%</b>	<b>Pyrogen: (USP 24) Sterility: Sterile (USP 24)</b>	<b>Pyrogen: Non- pyrogenic (USP 24)</b>	<b>Number of samples analyzed</b>
<b>Batch: Pilot 01</b>								
40°C	30 days	Conforms	5.6	99.8%	101.2%	-	-	3 units
	60 days	Conforms	5.8	99.6%	100.7%	-	-	3 units
	90 days	Conforms	5.2	99.1%	99.7%	-	-	3 units
	180 days	Conforms	5.5	98.7%	99.0%	Sterile	Non-pyrogenic	13 units
50°C	30 days	Conforms	5.7	99.7%	101.3%	-	-	3 units
	60 days	Conforms	5.1	99.4% <sup>..</sup>	100.8%	-	-	3 units
	90 days	Conforms	5.5	98.8%	99.8%	Sterile	Non-pyrogenic	13 units

**TABLE II: STABILITY STUDY**

Product: Ganciclovir in glucose 5% solution (1mg/mL)

Batch Number: Pilot 2 Manufacturing Date: Feb/2000

Batch size: 100 units

Packing: Tri-laminate plastic bag - 250mL

5 Results:

**Long term stability Study - 30°C ± 2°C:**

Tests	Specification	Beginning	6 months	9 months	12 months	24 months
Description/ color	Clear colorless liquid	Conforms	Conforms	Conforms	Conforms	Conforms
Assay Ganciclovir	90% to 110%	98.6%	98.0%	97.8%	97.5%	96.9%
Assay Glucose	95% to 105%	99.6%	99.2%	98.8%	98.0%	97.8%
pH	3.2 a 6.5	4.8	5.0	5.1	4.9	5.0
Sterility	Sterile	Sterile	-	-	-	Sterile
Pyrogen	Non-pyrogenic	Non- pyrogenic	-	-	-	Non- pyrogenic
Number of samples analyzed	-	13 units	3 units	3 units	3 units	13 units

Accelerated Stability:

The Injectable solution of Ganciclovir in glucose 5% was submitted in its primary packing to study in ovens at temperatures of 40°C and 50°C for periods of 180 and 90 days respectively. Bags placed at 40°C were analyzed in periods of 30, 60, 90 and 180 days, and bags placed at 50°C were analyzed in periods of 30, 60 and 90 days.

Tests		Aspect: Clear colorless liquid	pH 3.2 to 6.5	Glucose Assay: 95% to 105%	Ganci- clovir Assay: 90% to 110%	Pyrogen: (USP 24) Sterility: Sterile (USP 24)	Pyrogen: Non- pyrogenic (USP 24)	Number of samples analyzed
Batch: <b>Pilot 02</b>								
40°C	30 days	Conforms	4.8	98.6%	99.6%	-	-	3 units
	60 days	Conforms	5.1	98.2%	99.0%	-	-	3 units
	90 days	Conforms	5.0	97.7%	98.7%	-	-	3 units
	180 days	Conforms	5.3	97.2%	98.0%	Sterile	Non- pyrogenic	13 units
50°C	30 days	Conforms	4.9	98.7%	99.7%	-	-	3 units
	60 days	Conforms	5.0	98.4%	99.2%	-	-	3 units
	90 days	Conforms	5.2	97.8%	98.8%	Sterile	Non- pyrogenic	13 units

**TABLE III: STABILITY STUDY**

Product: Ganciclovir in glucose 5% solution (1mg/mL)

Batch Number: Pilot 3 Manufacturing Date: Feb/2000

Batch size: 100 units

5 Packing: Tri-laminate plastic bag - 250mL

Results:

**Long term stability Study - 30°C ± 2°C:**

Tests	Specification	Beginning	6 months	9 months	12 months	24 months
Description/ color	Clear colorless liquid	Conforms	Conforms	Conforms	Conforms	Conforms
Assay	90% to 110%	99.5%	99.0%	98.5%	98.0%	97.8%

<b>Ganciclo-vir</b>						
<b>Assay Glucose</b>	95% to 105%	98.9%	98.2%	98.4%	98.2%	98.0%
<b>pH</b>	3.2 to 6.5	4.8	5.0	5.1	5.2	5.0
<b>Sterility</b>	Sterile	Sterile	-	-	-	Sterile
<b>Pyrogen</b>	Non-pyrogenic	Non-pyrogenic	-	-	-	Non-pyrogenic
<b>Number of samples analyzed</b>	-	13 units	3 units	3 units	3 units	13 units

Accelerated Stability:

The Injectable solution of Ganciclovir in glucose 5% was submitted in its primary packing to study in ovens at temperatures of 40°C and 50°C for periods of 180 and 90 days respectively. Bags placed at 40°C were analyzed in periods of 30, 60, 90 and 180 days, and bags placed at 50°C were analyzed in periods of 30, 60 and 90 days.

Tests	Aspect: clear colorless liquid	pH : 3.2 to 6.5	Assay Glicose 95% to 105%	Assay Ganci- clovir 90% to 110%	Pyrogen: (USP 24) Sterility: Sterile (USP 24)	Pyrogen: Non- pyrogenic (USP 24)	Number of samples analyzed
Batch: Pilot 03							
40°C	30 days	Conforms	4.8	98.8%	99.2%	-	3 units
	60 days	Conforms	5.2	97.8%	98.8%	-	3 units
	90 days	Conforms	5.0	97.1%	98.2%	-	3 units
	180 days	Conforms	5.2	97.0%	97.6%	Sterile Non- pyrogenic	13 units
50°C	30 days	Conforms	4.9	98.7%	99.4%	-	3 units

	60 days	Conforms	5.1	98.4%	99.0%	-	-	3 units
	90 days	Conforms	5.0	97.8%	98.8%	Sterile	Non-pyrogenic	13 units

**TABLE IV: STABILITY STUDY**

Product: Ganciclovir in sodium chloride 0.9% solution (1mg/mL)

Batch Number: Pilot Manufacturing Date: Aug/2002

Batch size: 100 units

5 Packing: Tri-laminate plastic bag - 250mL

Results:

**Long term stability Study - 30°C ± 2°C:**

Tests	Specification	Beginning	6 months	9 months	12 months	24 months
Description/color	Clear colorless liquid	Conforms	Conforms	Conforms	Conforms	Conforms
Assay Ganciclo-vir	90% a 110%	98.20%	96.70%	92.66%	95.20%	95.00%
Assay Sodium chloride (0.9%)	95% a 105%	100.00%	100.50%	100.00%	99.80%	99.50%
pH	4.5 to 7.0	5.71	5.13	6.21	5.74	5.7
Sterility	Sterile	Sterile	-	-	-	Sterile
Pyrogen	Non-pyrogenic	Non-pyrogenic	-	-	-	Non-pyrogenic
Number of samples analyzed		13 units	3 units	3 units	3 units	13 units

Accelerated Stability:

The Injectable solution of Ganciclovir in sodium chloride 0.9% was submitted in its primary packing to study in ovens at temperatures of 40°C and 50°C for periods of 180 and 90 days respectively. Bags placed at 40°C were analyzed in periods of 30, 5 60, 90 and 180 days, and bags placed at 50°C were analyzed in periods of 30, 60 and 90 days.

Tests		Aspect: Clear colorless liquid	pH : 4.5 to 7.0	Assay NaCl 0.9%: 95% to 105%	Assay Ganci- clovir 90% to 110%	Pyrogen: Non- pyrogenic (USP 24)	Sterility: Sterile (USP 24)	Number of samples analyzed
Batch: Pilot								
40°C	30 days	Conforms	5.46	98.30%	100.00%	-	-	3 units
	60 days	Conforms	5.59	98.00%	101.20%	-	-	3 units
	90 days	Conforms	5.30	97.50%	100.50%	-	-	3 units
	180 days	Conforms	5.32	97.00%	99.80%	Non- pyrogenic	Sterile	13 units
50°C	30 days	Conforms	5.33	99.92%	100.60%	-	-	3 units
	60 days	Conforms	5.48	98.30%	100.60%	-	-	3 units
	90 days	Conforms	5.29	97.50%	99.5%	Non- pyrogenic	Sterile	13 units

**TABLE V: STABILITY STUDY**

Product: Ganciclovir (1mg/mL) in sodium chloride 0.9% solution  
 10 Batch Number: Piloto 02 Manufacturing Date: Feb./2002

Batch size: 100 units

Packing: Tri-laminate plastic bag - 250mL

Results:

**Long term stability Study - 30°C ± 2°C:**

5

Tests	Specification	Beginning	6 months	9 months	12 months	24 months
Description/ color	Clear colorless liquid	Conforms	Conforms	Conforms	Conforms	Conforms
Assay Ganciclovir	90% to 110%	101,2%	100,8%	99,8%	98,5%	97,7%
Assay Sodium chloride	95% to 105%	99,0%	98,7%	98,6%	98,6%	98,4%
pH						
Sterility	Sterile	Sterile	-	-	-	Sterile
Pyrogen	Non-pyrogenic	Non-pyrogenic	-	-	-	Non-pyrogenic
Number of samples analyzed		13 units	3 units	3 units	3 units	13 units

Accelerated Stability:

The Injectable solution of Ganciclovir in sodium chloride was submitted in its primary packing to study in ovens at temperatures of 40°C and 50°C for periods of 180 and 90 days respectively. The 10 Bags were analyzed in periods of 30, 60, 90 and 180 days when stored in ovens at 40°C; 30, 60 and 90 days when stored in ovens at 50°C.

Tests		Aspect: Clear colorles s liquid	pH :	Assay NaCl: 95% to 105%	Assay Ganci- clovir 90% to 110%	Pyrogen: Non- pyrogeni c (USP 24)	Sterility : Sterile (USP 24)	Number of samples analyzed
Batch: Pilot 02								
40°C	30 days	Conforms		99,1%	101,2%	-	-	3 units
	60 days	Conforms		98,8%	100,2%	-	-	3 units
	90 days	Conforms		98,7%	99,7%	-	-	3 units
	180 days	Conforms		98,7%	98,4%	Sterile	Non- pyrogenic	13 units
50°C	30 days	Conforms		99,0%	101,3%	-	-	3 units
	60 days	Conforms		98,6%	100,8%	-	-	3 units
	90 days	Conforms		98,5%	99,8%	Sterile	Non- pyrogenic	13 units

Only as illustrating, as described in literature related to

the issue (Guideline for Parenteral Administration of Antimicrobials F. Hoffmann - La Roche Ltd, Basel - Switzerland) the following recommendations are necessary for administration of

5 Ganciclovir as described in the state of art, evidencing the profoundness of the inventive activity of the present invention, which advantages over the state of art are evident:

[RECOMMENDATION] [BOLUS INTRAVENOUS]

[INTERMITTENT PERfusion] [CONTINUOUS INTRAVENOUS]

10 [INTRAMUSCULAR] [COMPATIBLE SOLUTIONS]

**[STABILITY] [OBSERVATIONS]**

**RECOMMENDATION**

Reconstitute each vial with 10mL of sterile water for injection and dilute in an acceptable volume of infusion solution,  
5 administrating it by intravenous infusion for a period of approximately one hour.

**BOLUS INTRAVENOUS**

No. Toxicity may increase.

**INTERMITTENT PERfusion**

10 Yes. Dilute the reconstituted content in an infusion solution and deliver it over the course of one hour.

**CONTINUOUS INTRAVENOUS**

Do not recommended due the risk of bacterial contamination.

**INTRAMUSCULAR**

15 Yes, but can cause irritation in the site of the injection due the elevate pH of the injectable solution (pH ~ 11). It also can be done by subcutaneous administration, but with the same local irritation risk.

**COMPATIBLE SOLUTIONS**

20 Sodium chloride 0.9% aqueous solution.

Glucose 5% aqueous solution.

Ringer solution.

Ringer lactated solution.

**STABILITY**

25 12 hours under room temperature when reconstituted inside its own vial.

When diluted ,use it as soon as possible because the risk of bacterial contamination. If it is not possible to use it immediately, keep it under refrigeration for a maximum period of 24  
30 hours, avoiding freezing.

**OBSERVATIONS**

Do not dilute with bacteriostatic water. Only use sterile bi-distilled water for injection.

Inspect the vial after reconstitution to avoid presence of particulate matter or discoloration.

5 Not less important is described, also as illustrative matter, in the Technical Opinion nº 005/95 from Conselho Federal de Farmacia - Brazil, about the Validation of Technical Analysis Appropriate to Products and By-products Resulting from obtaining the New Developed Molecule.

10 Subject: Preparing and administering intravenous Ganciclovir and Amphotericin B.

#### Analysis

Considering the solicitation issued in the Conselho Federal de Farmacia that forwarded the following informations:

15 Ganciclovir, an antiviral agent, is considered a risk drug because its carcinogenic and mutagenic properties. So, care must be taken when manipulating, preparing and administering it.

Because the resulting solution is strongly alkaline (pH=11) and irritating after its reconstitution, one must avoid the contact  
20 with the skin, mucous membranes and the eyes. Using glasses and gloves are necessary when manipulating it.

In accordance with protocols from the American Society of Hospital Pharmacy - ASHP, Ganciclovir must be manipulated and prepared inside laminar flow chambers, preventing the contamination  
25 of the product by microorganisms and protecting the individual and the environment from potential risks of the medicament. The appropriate equipment for carrying this operation is a class II vertical laminar flow chamber BSC (bio-security chamber).

Initially, Amphotericin B (a fungicide) must be reconstituted  
30 with 10mL of sterile water for injection, without bacteriostatic agent, for achieving a concentration of 5mg/mL, forming a colloidal suspension. For the intravenous infusion, the colloidal suspension

must be diluted to 500mL with glucose 5% solution, reaching a concentration of 0.1mg/mL.

Solutions containing electrolytes (for instance NaCl 0.9%) or containing bacteriostatic agents should not be used for  
5 reconstituting and/or diluting Amphotericin B, because there is the risk of precipitating the drug.

Amphotericin B, for administration by intravenous infusion must be prepared according to rigorous aseptic techniques, it means, using sterile gloves, needles and syringes, by cleaning the  
10 vial top with a cotton soaked in alcohol, etc.

Although Amphotericin B is sensible to light, it is not necessary to cover the infusion bag, if the administration takes place within until 8 hours after its preparation.

Considering that new drugs are being launched for treating  
15 immunodepressed patients everyday and it is very much usual the lack of knowledge of the health professional personnel about the risks that they could be exposed to when preparing and administering these drugs, it is necessary for them to keep under a constant upgrading program.

20

25

CLAIMS

1. PROCESS OF OBTAINING 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one CRYSTALS FOR USE IN GLUCOSED SERUM FREE FROM ALKALINE RESIDUES FOR USE IN GLUCOSE SOLUTION,  
5 characterized by the following steps:

- (a) Suspending in a glass reactor coupled with a condenser apparatus 90 to 110g of 9-((1,3-DIHYDROXYPROPAN-2-ILYOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE (free base) in 0.9 to 1.1 l of demineralized water under strong stirring and room temperature until complete homogenization and obtaining of aqueous 9-((1,3-DIHYDROXYPROPAN-2-ILYOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE (free base);  
10  
(b) Adding under stirring to the obtained in (a) 13.5 to 16.5g inorganic bases, pH between 10.5 to 12.5 until the total dissolution of the suspension;  
15  
(c) Heating the solution obtained in (b) under stirring to a temperature range from 75° to 90°C and adding 5.4 to 6.6g of acids until a pH range from 4.5 to 5.5;  
20  
(d) Cooling the solution obtained in (c) under stirring to a temperature range from 5° to 7°C and obtain the crystallization of 9-((1,3-DIHYDROXYPROPAN-2-ILYOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE (free base) and maintain the suspension under stirring, in the cited temperature, for 25 to 40 minutes;  
25  
(e) Filtering the solid obtained in (d) after 25 to 40 minutes under stirring in a temperature from 5° to 7°C and wash the crystals with solvents;  
30  
(f) Transferring the obtained 9-((1,3-DIHYDROXYPROPAN-2-ILYOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE crystals to a glass reactor coupled with a condenser and adding

ethanol, methanol, propanol, butanol or isopropanol solvents in the range from 4 to 6 parts in relation with the 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE crystal mass and heating the suspension under stirring and intensively reflux for 3 to 4 hours;

5 (g) Cooling the suspension obtained in (f) to a room temperature between 20° to 30°C and proceed with a filtration;

10 (h) Drying the 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE (free base) crystals obtained in

(g) in vacuum oven for 3 to 5 hours at a temperature from 60° to 80°C; and

15 (i) Obtaining 90,4 to 100,4g of the 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE (free base) dry product and with a final yield between 89 to 98%.

2. **PROCESS** in accordance with claim 1, characterized by the fact that in the step (a) is used 1 liter of demineralized water in the proportion of 8 to 20 parts of demineralized water to 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE.

20 3. **PROCESS** in accordance with claim 2, characterized by the fact that the proportion is 10 parts.

4. **PROCESS** in accordance with claim 1, characterized by the fact that is added in the step (b) 15g of inorganic bases from the group of: potassium hydroxide, lithium hydroxide or sodium hydroxide.

25 5. **PROCESS** in accordance with claim 4, characterized by the fact that is used preferably sodium hydroxide, in the quantity from

0.9 to 2.0 mols of sodium hydroxide per mol of 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE.

6. **PROCESS** in accordance with claim 5, characterized by the fact  
that is used the sodium hydroxide in the quantity of 1.1 mol of  
5 sodium hydroxide in relation of 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE, with pH of 11,5.
7. **PROCESS** in accordance with claim 1, characterized by the fact  
that in the step (c) the preferential temperature is 85°C and  
the acids used are fuming hydrochloric acid, hydrofluoric acid,  
10 acetic acid or citric acid and preferably in a concentration of  
6g.
8. **PROCESS** in accordance with claim 7, characterized by the fact  
that is used preferably the fuming hydrochloric acid and the pH  
preferably is 4.5.
- 15 9. **PROCESS** in accordance with claim 1, characterized by the fact  
that in the step (d) the preferably temperature is 5°C and the  
preferably period of time is 30 minutes.
10. **PROCESS** in accordance with claim 1, characterized by the fact  
that in the step (e) the filtration occurs with the water in a  
20 temperature from 5 to 7°C in the proportion of 1/10 of the used  
water volume in the beginning of the process and the crystal is  
washed with organic solvents based on acetone, ethanol,  
methanol or isopropanol.
11. **PROCESS** in accordance with claim 10, characterized by the fact  
25 that the organic solvent used is preferably the isopropanol.

12. **PROCESS** in accordance with claim 1, characterized by the fact that in the step (f) the re-suspension occurs preferably in 4 hours and the preferably solvent is the isopropanol.
13. **PROCESS** in accordance with claim 1, characterized by the fact that in the step (g) the cooling temperature preferably is 25°C.
14. **PROCESS** in accordance with claim 1, characterized by the fact that in step (h) the drying occurs preferably in 4 hours at a preferably temperature of 70°C.
- 10 15. **9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE CRYSTALS SOLUTION FREE FROM ALKALINE RESIDUES** characterized by the fact that the glucose pre-diluted solution containing the active principle is presented in the form of a clear solution without oxidation and with the pH about 5.5.
- 15 16. **PACKAGING PROCESS OF THE 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE CRYSTALS SOLUTION FREE FROM ALKALINE RESIDUES** characterized by the fact that the glucose pre-diluted solution with 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE is packaged in a closed system.
- 20 17. **USE OF THE CLOSED SYSTEM** characterized by the fact that it is for the packaging of the 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE crystals pre-solution free from alkaline residues.
- 25 18. **USE** in accordance with claim 17 characterized by the fact that the solution is packaged in a flexible three-laminated plastic bag.

19. **USE** in accordance with claim 18 characterized by the fact that the bag has three different layers.
20. **USE** in accordance with claims 18 and 19, characterized by the fact that the outer layer is made of polyester, the intermediate layer is made of polyethylene and the inner layer of propylene copolymer.
- 5
21. **USE** in accordance with claim 20 characterized by the fact that the polyester resists to the heat and has resistance against abrasion and mechanical stress, the polyethylene gives flexibility and works as a barrier against moisture and vapors exchange with the environment and the propylene copolymer is impermeable, flexible and inert.
- 10
22. **USE OF THE SOLUTION** of the claim 15 characterized by being in the treatment of immunodepressed patients carrying viral infections.
- 15
23. **USE** in accordance with claim 22 characterized by being in the treatment of AIDS carrying individuals and immunotransplanted.
24. **USE** in accordance with claim 22 characterized by being in the fight against a wide spectrum viral infections including Epstein-Barr virus, cytomegalovirus, adenovirus, herpes zoster virus and herpes virus type 1 and 2.
- 20
25. **USE OF THE CLOSED SYSTEM** from claims 17 to 21 characterized by being in the treatment of immunodepressed patients carrying viral infections.
- 25
26. **USE** in accordance with claim 25 characterized by being in the treatment of AIDS carrying individuals and immunotransplanted.

27. **USE** in accordance with claim 25 characterized by being in the fight against a wide spectrum viral infections including Epstein-Barr virus, cytomegalovirus, adenovirus, herpes zoster virus and herpes virus type 1 and 2.

5       28. **USE** of the 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE crystals, characterized by the fact that are alkaline free, for the preparation of glucose pre-diluted solutions packaged in closed system, to be used in the treatment of immunodepressed patients carrying viral  
10      infections.

29. **USE** in accordance with claim 28 characterized by being in the treatment of AIDS carrying individuals and immunotransplanted.

30. **USE** in accordance with claim 28 characterized by being in the fight against a wide spectrum viral infections including  
15      Epstein-Barr virus, cytomegalovirus, adenovirus, herpes zoster virus and herpes virus type 1 and 2.

20

25

## ABSTRACT

"PROCESS OF OBTAINING 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one CRYSTALS FOR USE IN GLUCOSED SERUM; SOLUTION BASED ON SAID CRYSTALS FREE FROM ALKALINE RESIDUES; 5 PROCESS AND USE OF CLOSED SYSTEM IN THE PACKAGING OF THE SOLUTION; AND USE OF THE SOLUTION AND OF THE SYSTEM IN THE TREATMENT OF DESEASES."

The invention discloses a process of obtainment of 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE (GANCICLOVIR) crystals free from alkaline residues. The pre-diluted solution is presented ready for teh administration to the patient, being packaged in closed system, avoiding the contamination risks. Discloses too a pre-diluted solution of 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE crystals free from 10 alkaline residues; the packaging process of the injectable pré-dilutes solution obtained in closed system, and to the use of the cited ganciclovir crystals, free from alkaline residues, in glucose solution; to the use in closed system for the packaging of the 15 solution and the use of the solution and the closed system against diseases.

By the process of the present invention was developed a product that presents as it principle characteristics the fact that it is steril, it is proper to be packaged in closed system by sterile plastic bag, it is stable, has its pH proper to be packaged 20 in closed system, wich is the same of the solution. The stabilization reach of the final product occured because the altering of the 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-PURIN-6(9H)-ONE molecule crystal kind.

The present invention concludes that the use of the pre-30 diluted preparations, in closed system, reduce the risks of errors in the drug administration, also reducing the steps of drug

manipulation by the hospital nurse staff, besides of contribute to reduce the contamination risks.

The product obtained by the present invention is presented in the form of a 9-((1,3-DIHYDROXYPROPAN-2-ILOXY)METHYL)-2-AMINO-1H-5 PURIN-6(9H)-ONE (Ganciclovir) glucose solution packaged in a flexible plastic bag (closed system), preferable prepared with the use of trilaminated plastic.

The present invention is related with the therapeutic and medical sectors, principally with the treatment of immunodepressed 10 patients carrying viral infections.